Search

Dennis Zaller Phones & Addresses

  • Needham, MA
  • 807 Raritan Rd, Scotch Plains, NJ 07076
  • Edison, NJ
  • Pasadena, CA
  • Rahway, NJ
  • Kansas City, KS
  • Oscar, LA
  • Union, NJ
  • Walpole, MA

Work

Company: Merck Sep 1990 to Sep 2013 Position: Executive director

Education

Degree: Ph.D. School / High School: Columbia University in the City of New York 1984 to 1987 Specialities: Biological Sciences

Industries

Pharmaceuticals

Resumes

Resumes

Dennis Zaller Photo 1

Executive Director At Merck &Amp; Co. Inc.

View page
Position:
Executive Director at Merck
Location:
Greater New York City Area
Industry:
Pharmaceuticals
Work:
Merck since Sep 1990
Executive Director

California Institute of Technology Sep 1987 - Aug 1990
Senior Research Fellow
Education:
Columbia University in the City of New York 1984 - 1987
Ph.D., Biological Sciences
State University of New York at Albany 1976 - 1979
B.S., Biology

Publications

Us Patents

Src Kinase Inhibitor Compounds

View page
US Patent:
6498165, Dec 24, 2002
Filed:
Jun 26, 2000
Appl. No.:
09/604305
Inventors:
Helen M. Armstrong - Westfield NJ
Richard Beresis - New York NY
Joung L. Goulet - Westfield NJ
Mark A. Holmes - Middlesex NJ
Xingfang Hong - Westfield NJ
Sander G. Mills - Scotch Plains NJ
William H. Parsons - Belle Mead NJ
Peter J. Sinclair - Scotch Plains NJ
Mark G. Steiner - East Brunswick NJ
Frederick Wong - Glen Ridge NJ
Dennis M. Zaller - Scotch Plains NJ
Assignee:
Merck Co., Inc. - Rahway NJ
International Classification:
A61K 31505
US Classification:
514275, 514256, 5142581, 544330, 544331
Abstract:
Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of protein tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.

High Affinity Antibody Antagonists Of Interleukin-13 Receptor Alpha 1

View page
US Patent:
7754213, Jul 13, 2010
Filed:
Oct 19, 2007
Appl. No.:
11/875017
Inventors:
Andrew Donald Nash - Kew,
Manuel Baca - Gaithersburg MD,
Louis Jerry Fabri - Diamond Creek,
Dennis Zaller - Scotch Plains NJ,
William R. Strohl - Bridgewater NJ,
Zhiqiang An - Ambler PA,
Assignee:
Merck & Co., Inc. - Rahway NJ
CSL Limited - Parkville, Victoria
International Classification:
A61K 39/395
US Classification:
4241421, 4241431, 4241541, 53038815, 53038822, 53038875
Abstract:
High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.

High Affinity Antibody Antagonists Of Interleukin-13 Receptor Alpha 1

View page
US Patent:
8568722, Oct 29, 2013
Filed:
May 6, 2010
Appl. No.:
12/774966
Inventors:
Andrew Donald Nash - Kew,
Manuel Baca - Gaithersburg MD,
Louis Jerry Fabri - Diamond Creek,
Dennis Zaller - Scotch Plains NJ,
William R. Strohl - Bridgewater NJ,
Zhiqiang An - Ambler PA,
Assignee:
CSL Limited - Parkville, Victoria
International Classification:
A61K 39/395
US Classification:
4241441
Abstract:
High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.

Anti-Il-13Rα1 Antibodies And Their Uses Thereof

View page
US Patent:
8613925, Dec 24, 2013
Filed:
Oct 19, 2007
Appl. No.:
12/445753
Inventors:
Andrew Donald Nash - Kew,
Manuel Baca - Gaithersburg MD,
Louis Jerry Fabri - Diamond Creek,
Dennis Zaller - Scotch Plains NJ,
William R. Strohl - Bridgewater NJ,
Zhiqiang An - Ambler PA,
Assignee:
CSL Limited - Parkville, Victoria
International Classification:
A61K 39/395
US Classification:
4241441
Abstract:
Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13Rα1 through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13Rα1-mediated activities are also disclosed.

Antibody Antagonists Of Interleukin-13 Receptor Α1

View page
US Patent:
8207304, Jun 26, 2012
Filed:
Oct 19, 2007
Appl. No.:
12/445759
Inventors:
Andrew Donald Nash - Kew,
Louis Jerry Fabri - Diamond Creek,
Dennis Zaller - Scotch Plains NJ,
William R. Strohl - Bridgewater NJ,
Zhiqiang An - Ambler PA,
Assignee:
CSL Limited - Parkville
International Classification:
C07K 16/00
C12N 15/13
US Classification:
5303871, 536 2353
Abstract:
Antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are useful in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.

Phenyl Substituted Imidaopyridines And Phenyl Substituted Benzimidazoles

View page
US Patent:
2005016, Jul 28, 2005
Filed:
May 9, 2003
Appl. No.:
10/513932
Inventors:
Richard Beresis - Matawan NJ,
Steven Colletti - Princeton Junction NJ,
James Doherty - Montvale NJ,
Dennis Zaller - Scotch Plains NJ,
International Classification:
C07D043/02
A61K031/501
US Classification:
544238000, 514252060
Abstract:
Compounds described by the formula (I) or formula (II): (I), (II), or pharmaceutically acceptable salts thereof, are inhibitors of p38 useful in the treatment of inflammatory diseases such as arthritis. Compounds may be selective adenosine A1 antagonists useful in the treatment of neurological disorders such as dementia and depression.

High Affinity Antibody Antagonists Of Interleukin-13 Receptor Alpha 1

View page
US Patent:
2014005, Feb 27, 2014
Filed:
Oct 14, 2013
Appl. No.:
14/052791
Inventors:
- Parkville,
Manuel Baca - Gaithersburg MD,
Louis Jerry Fabri - Diamond Creek,
Dennis Zaller - Scotch Plains NJ,
William R. Strohl - Bridgewater NJ,
Zhiqiang An - Ambler PA,
Assignee:
CSL Limited - Parkville
International Classification:
C07K 16/28
US Classification:
4241721, 5303891
Abstract:
High affinity antibody antagonists of human interleukin-13 receptor alpha 1 are disclosed. The antibody molecules are effective in the inhibition of IL-13Rα1-mediated activities and, accordingly, present desirable antagonists for the use in the treatment of conditions associated with hIL-13Rα1 activity. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing IL-13Rα1-mediated activities are also disclosed.

Src Kinase Inhibitor Compounds

View page
US Patent:
6329380, Dec 11, 2001
Filed:
Jun 26, 2000
Appl. No.:
9/603688
Inventors:
Joung L. Goulet - Westfield NJ
Mark A. Holmes - Middlesex NJ
Julianne A. Hunt - Princeton NJ
Sander G. Mills - Scotch Plains NJ
William H. Parsons - Belle Mead NJ
Peter J. Sinclair - Scotch Plains NJ
Dennis M. Zaller - Scotch Plains NJ
Assignee:
Merck & Co., Inc. - Rahway NJ
International Classification:
C07D40114
C07D40314
A61K 31506
A61K 31519
A61P 1706
US Classification:
514261
Abstract:
Pyrimidine compounds (Formula I), or their pharmaceutically acceptable salts, hydrates, solvates, crystal forms and individual diastereomers, and pharmaceutical compositions including the same, which are inhibitors of tyrosine kinase enzymes, and as such are useful in the prophylaxis and treatment of proteins tyrosine kinase-associated disorders, such as immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to play a role, such as cancer, angiogensis, atheroscelerosis, graft rejection, rheumatoid arthritis and psoriasis.
Dennis M Zaller from Needham, MA, age ~61 Get Report